E3 PreliminaryPreliminaryPEM not requiredReview-NarrativePeer-reviewedReviewed
The emerging role of exosomal LncRNAs in chronic fatigue syndrome: from intercellular communication to disease biomarkers.
Wang, Lei, Xu, Yujia, Zhong, Xiang et al. · Frontiers in molecular biosciences · 2025 · DOI
Quick Summary
This review examines tiny packages called exosomes that cells release into the body, which contain special molecules called long noncoding RNAs (lncRNAs). These molecules may help cells communicate with each other and could be involved in ME/CFS. The researchers explored whether these lncRNAs could potentially be used as biological markers to help doctors identify and diagnose ME/CFS earlier.
Why It Matters
ME/CFS currently lacks reliable diagnostic biomarkers and disease-modifying treatments, creating significant diagnostic and clinical challenges. This review identifies exosomal lncRNAs as a novel research avenue that could lead to better understanding of disease mechanisms and development of diagnostic tools and targeted therapies for patients.
Observed Findings
- Exosomes contain lncRNAs that can mediate inter-organ and inter-cellular communication
- Multiple body systems are involved in ME/CFS pathology, suggesting systemic dysfunction mechanisms
- No currently validated biomarkers exist for early identification and diagnosis of ME/CFS
- Exosomal lncRNAs represent a previously underexplored avenue for understanding ME/CFS pathogenesis
Inferred Conclusions
- Exosomal lncRNAs may play a role in ME/CFS pathophysiology through intercellular communication mechanisms
- EV-lncRNAs have potential as biomarkers for early identification and diagnosis of ME/CFS
- Further research into exosomal lncRNAs could reveal novel therapeutic targets for ME/CFS treatment
Remaining Questions
- Which specific lncRNAs are dysregulated in ME/CFS patients and how do they differ from healthy controls?
- Can exosomal lncRNA profiles reliably diagnose ME/CFS and distinguish it from other chronic conditions with similar symptoms?
- What are the mechanisms by which altered exosomal lncRNAs contribute to ME/CFS symptoms such as post-exertional malaise and cognitive dysfunction?
What This Study Does Not Prove
This is a review article that does not present primary research data or clinical evidence. It does not prove that exosomal lncRNAs cause ME/CFS or that they can serve as practical diagnostic biomarkers—only that they warrant further investigation. The study presents theoretical mechanisms and potential associations rather than established causal relationships.
Tags
Symptom:Fatigue
Biomarker:Gene ExpressionBlood Biomarker
Method Flag:Exploratory Only
Metadata
- DOI
- 10.3389/fmolb.2025.1653627
- PMID
- 40950577
- Review status
- Editor reviewed
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.